time
first
monoclon
antibodi
gener
first
monoclon
antibodi
fulli
licenc
field
monoclon
antibodi
develop
repres
novel
way
target
specif
mutat
defect
protein
structur
express
wide
rang
diseas
condit
today
major
rapid
advanc
genet
sequenc
translat
basic
medic
scienc
research
clinic
practic
humanis
monoclon
antibodi
fastest
grow
group
biotechnologyderiv
molecul
clinic
trial
current
global
valu
antibodi
market
approxim
billion
per
year
monoclon
antibodi
current
approv
fda
use
human
treat
variou
diseas
condit
includ
cancer
chronic
inflammatori
diseas
transplant
infecti
diseas
cardiovascular
diseas
monoclon
antibodi
monoval
antibodi
bind
epitop
produc
singl
blymphocyt
clone
first
gener
mice
use
hybridoma
techniqu
gener
hybridoma
involv
immunis
certain
speci
specif
epitop
antigen
obtain
blymphocyt
spleen
anim
blymphocyt
fuse
chemic
virusinduc
method
immort
myeloma
cell
line
lack
hypoxanthineguaninephosphoribosyltransferas
hgprt
gene
contain
immunoglobulinproduc
cell
hybridoma
cell
cultur
vitro
select
medium
ie
medium
contain
hypoxanthineaminopterinthymidin
hybridoma
ie
fusion
primari
blymphocyt
myeloma
cell
surviv
inherit
immort
myeloma
cell
selectiveresist
primari
blymphocyt
myeloma
cell
lack
hgprt
synthesis
nucleotid
de
novo
inhibit
aminopterin
select
medium
initi
cultur
hybridoma
contain
mixtur
antibodi
deriv
mani
differ
primari
blymphocyt
clone
secret
individu
specif
antibodi
cultur
medium
ie
antibodi
still
polyclon
individu
clone
separ
dilut
differ
cultur
well
cell
cultur
medium
screen
mani
hundr
differ
well
specif
antibodi
activ
requir
desir
blymphocyt
grown
posit
well
reclon
retest
activ
posit
hybridoma
monoclon
antibodi
gener
store
away
liquid
nitrogen
first
licenc
monoclon
antibodi
orthoclon
approv
use
prevent
kidney
transplant
reject
monoclon
mous
antibodi
whose
cognat
antigen
work
bind
block
effect
express
tlymphocyt
howev
use
limit
acut
case
due
report
sideeffect
eg
human
antimous
antibodi
respons
repres
rel
lack
earli
clinic
commerci
success
monoclon
antibodi
major
stumbl
block
fact
product
earli
monoclon
antibodi
limit
whether
suitabl
myeloma
cell
line
avail
usual
mous
rat
hybridoma
may
also
low
yield
genet
unstabl
recent
mani
differ
express
system
monoclon
antibodi
test
contrast
effect
exampl
e
coli
found
excel
system
express
antibodi
fragment
singlechain
variabl
fragment
scfv
antigenbind
fragment
fab
howev
synthesi
rel
larger
fullsiz
antibodi
ie
consist
heavi
chain
light
chain
join
togeth
disulphid
bridg
give
total
molecular
weight
kda
may
step
far
rel
small
microorgan
although
lack
glycosyl
enzym
e
coli
may
also
prove
benefici
antibodi
whose
primari
role
block
interact
oppos
invok
downstream
immun
effector
respons
eg
complement
system
lead
potenti
immunogen
sideeffect
also
transform
effici
thu
puriti
produc
humanis
monoclon
antibodi
found
low
use
transgen
anim
concept
involv
use
anim
speci
product
humanis
antibodi
exampl
endogen
mous
igg
gene
delet
transgen
mice
replac
human
copi
gene
immunis
mous
blymphocyt
synthesis
human
version
respect
antibodi
hybridoma
produc
advantag
includ
cognat
pair
variabl
heavi
light
domain
vhvl
pair
vivo
antibodi
matur
process
gener
higher
affin
bind
region
fulllength
igg
antibodi
produc
without
need
clone
obtain
easi
sourc
monoclon
antibodi
also
explor
express
monoclon
antibodi
mammalian
milk
gland
anoth
method
gener
monoclon
antibodi
use
phage
display
involv
isol
blymphocyt
blood
human
isol
mrna
convert
cdna
use
pcr
amplifi
vh
vl
segment
segment
clone
vector
usual
scfv
next
piii
protein
bacteriophag
use
infect
e
coli
order
gener
librari
contain
approxim
cell
inocul
librari
addit
helper
phage
e
coli
secret
bacteriophag
contain
vh
vl
segment
part
bacteriophag
coat
specif
vh
vl
segment
antigen
select
use
reinocul
e
coli
bacteriophag
cell
contain
plasmid
isol
sequenc
advantag
includ
librari
made
librari
use
gener
new
antibodi
remad
immunis
requir
entir
process
done
vitro
antibodi
obtain
much
quickli
tradit
hybridoma
techniqu
librari
use
gener
antibodi
toxic
antigen
could
use
immunis
anim
target
improv
antibodi
efficaci
includ
immunogen
antigenbind
affin
effector
function
pharmacokinet
immunogen
involv
minimis
nonhuman
sequenc
creat
chimer
humanis
human
version
antibodi
tlymphocyt
epitop
possibl
antibodi
fragment
usual
less
immunogen
due
lack
fc
domain
antigenbind
affin
improv
use
phage
display
librari
isol
antibodi
strong
affin
antigen
howev
sometim
antibodi
lower
affin
antigen
may
requir
allow
better
penetr
tumour
effector
function
improv
genet
engin
fc
region
contain
point
mutat
glycan
modif
yamaneohnuki
satoh
review
discuss
develop
defucosyl
antibodi
increas
affin
receptor
enhanc
antibodydepend
cellmedi
cytotox
adcc
particularli
interest
aspect
antibodi
efficaci
uniqu
pharmacokinet
characterist
insid
bodi
exampl
note
bioavail
igg
plasma
partial
depend
interact
neonat
fcbrambel
receptor
fcrn
fcrn
function
salvag
receptor
lead
rescu
igg
internalis
cell
degrad
lysosom
caus
recycl
antibodi
plasma
thu
prolong
halflif
plasma
halflif
igg
also
increas
develop
antibodi
eg
phage
display
increas
affin
fcrn
antibodi
fragment
treat
polyethylen
gycol
pegyl
also
shown
increas
plasma
halflif
monoclon
antibodi
also
modifi
order
addit
effect
well
teicher
chari
discuss
possibl
conjug
antibodi
involv
coupl
effector
molecul
monoclon
antibodi
eg
plantbacteri
toxin
enzym
radionuclid
cytotox
drug
etc
chemic
coupl
effector
molecul
monoclon
antibodi
usual
done
aid
chemic
ligand
ie
join
molecul
site
coupl
monoclon
antibodi
usual
includ
thiol
group
eg
group
cystein
residu
etc
amin
group
eg
group
lysin
residu
carbohydr
cystein
lysin
carbohydr
attach
site
ad
anywher
monoclon
antibodi
use
sitedirect
mutagenesi
although
function
monoclon
antibodi
must
impair
exampl
antibodi
bound
toxin
target
tumour
also
produc
genet
engin
dna
sequenc
code
specif
toxin
ad
end
scfv
chain
region
genom
transcrib
time
bispecif
antibodi
target
separ
epitop
arm
fab
portion
produc
chemic
crosslink
igg
fab
scfv
fragment
gener
hybrid
hybridoma
rel
lack
commerci
success
monoclon
antibodi
may
attribut
high
cost
administr
exampl
leukaemia
treatment
cost
approxim
year
suppli
alemtuzumab
furthermor
cancer
treatment
antibodi
rare
ever
cur
exampl
bevacizumab
avastin
extend
median
surviv
time
vs
month
compar
standard
chemotherapi
sideeffect
includ
firstinfus
reaction
eg
feverlik
symptom
thu
issu
surround
cost
administr
need
greater
clinic
efficaci
sideeffect
still
need
address
order
monoclon
antibodi
becom
commerci
viabl
factor
influenc
growth
commercialis
monoclon
antibodi
longterm
includ
qualiti
control
patient
complianc
competit
pharmaceut
market
incent
antibodi
develop
eg
infrastructur
reimburs
programm
etc
monoclon
antibodi
present
attract
option
develop
new
therapi
molecular
drug
target
wide
varieti
common
diseas
due
specif
flexibl
consider
choos
type
monoclon
antibodi
develop
includ
method
product
avid
effector
function
deliveri
target
tissu
eg
smaller
scfv
may
abl
penetr
tumour
effect
fullsiz
antibodi
howev
despit
drawback
still
major
interest
pharmaceut
compani
develop
monoclon
antibodi
clinic
diagnost
use
sure
dictat
futur
treatment
manag
common
chronic
condit
clinic
econom
point
view
author
declar
conflict
interest
author
declar
sourc
fund
use
prepar
manuscript
author
declar
ethic
approv
requir
prepar
manuscript
author
declar
consent
patient
requir
prepar
manuscript
jkhl
involv
studi
concept
design
data
collect
data
analysi
interpret
write
paper
justin
kh
liu
accept
full
respons
work
decis
publish
